Dr. Anjan Thakurta

Dr. Anjan Thakurta is an internationally recognized cancer scientist and drug developer. Anjan’s leadership and scientific contributions have led to 6 approved cancer drugs that have collectively been commercialized for over 20 years and created billions in revenue, while helping so many patients and families.  Anjan brings to BERG’s Scientific Advisory Board, more than 20 years of large pharma, biotech, and academic experience.  He is the Vice President, Translational Medicine at Bristol Myers Squibb and he also serves as Visiting Professor in Cancer Biology and Translational Sciences at Oxford University, UK.

Anjan received his MSc and MTech from Jawaharlal Nehru University and IIT Delhi, India followed by a doctorate from Cambridge University in Genetics. He went on to pursue post-doctoral training at Harvard University in molecular and cellular biology. After a stint at the NCI, Anjan worked in large pharma including AstraZeneca and Biogen Idec before joining Celgene in 2011. At Celgene, Anjan led multiple late-stage translational development and companion diagnostics programs including the Myeloma Genome Project (MGP). Anjan was part of the Celgene acquisition by BMS in 2020 when he stepped up into his current role. In addition to his responsibilities at BMS, Anjan continues to nurture and guide young scientists in translational medicine and loves mentoring future leaders.